Kajaria Ceramics Q3 Results Review - Systematix Maintains 'Hold' On The Stock — Here's Why

While long-term structural drivers are intact, on low earnings growth and margin of safety in the scrip at ~30x FY27E P/E, the brokerage maintains Hold rating with a target price of Rs 1,046

Close view of a person choosing tiles. (Source: freepik)

Kajaria Ceramics has set a three-year mission to achieve 150 million square metre tile volume, Rs 65 billion revenue (tiles 55 billion, bathware 6.75 billion, plywood 1.7 billion) and ~15.5% Ebitda margin.

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Research Report

Kajaria Ceramics Ltd. reported another quarter of weak operating performance as in Q3, tile volume grew by 7% YoY (inline, versus nil for industry) whereas revenue could grow only by 1% YoY (5% miss) on lower realization. Ebitda/PAT declined 17%/25% YoY (~15% miss).

Gross margin fell 43bps YoY to 58.8%; Ebitda margin contracted 274bps YoY to 12.8%. Margins in Q3 and 9M got impacted due to greater mix of project sales (40% versus earlier 30%) to push volume amid weak demand in retail channel.

Loss in bathware division stayed owing to commissioning of new Sanitaryware unit. Net cash stood lower at ~Rs 3 billion while working capital cycle came stable at 59 days.

After clocking 8% YoY growth in tile volume in 9M, Kajaria Ceramics aims 8-9% growth in FY25E. Nepal 5.1 million GVT plant achieved 70% capacity utilisation and is expected to increase to 85% by April 2025; its consolidation with Kajaria Ceramics will start from 1st Apr-25. Bathware revenue is aimed to grow at 10% YoY in FY25. Power and fuel costs remain stable.

Click on the attachment to read the full report:

Systematix Kajaria Ceramics Q3 FY25 - Results Review.pdf
Read Document

Also Read: Gland Pharma Q3 Results Review - Motilal Oswal Reiterates 'Buy' On New Launches, Higher Milestone Income

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story You must be an existing Premium User
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES